ONCY News and Press, Oncolytics Biotech Inc. From 04/28/22

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Canada NewsWire Conference call and webcast to take place on Thursday, May 5, 2022 , at 5:00 p.m. ET SAN DIEGO and CALGAR...

Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference PR Newswire SAN DIEGO, Calif. and CALGARY, AB , April 21,...

Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are...

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine Canada NewsWire - Pelareorep-CAR T combination may exp...

Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference Canada NewsWire SAN DIEGO, Calif. and CALGARY, AB , April 12, 2022 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC...

Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting Canada NewsWire - Results demonstrate meaningful and durable efficacy signal in a highly challenging indication - A higher...

Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress Canada NewsWire SAN DIEGO, Calif. and CALGARY, AB , April 6, 2022 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, inc...

Oncolytics Biotech (NASDAQ:ONCY) is trading ~11% higher premarket after it said no safety concerns were noted in the three-patient colorectal cancer group in phase 1/2 trial testing its drug, pelareorep in combination with Roche's (ROG) atezolizumab. The company said an in...

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial Canada NewsWire Independent review identified, no safety concerns in trial's final safety run-...